Other Information
−Removed: During the second quarter of
−Removed: 2024, none of our directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule
−Removed: 10b5-1 trading arrangement” (as each term is defined in Item 408(a) of Registration S-K).
−Removed: Exhibit Number
−Removed: Description of Exhibit
+Added: spouse of Lynn O’Connor Vos, the Chairperson of our Board of Directors, adopted a Rule 10b5-1 plan (“Rule 10b5-1 Plan”)
+Added: intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act with a start date of September 13, 2024.
+Added: The Rule 10b5-1 Plan provides for the sale of up to 9334 shares of the Company’s common stock held directly by Mr.
+Added: 10b5-1 Plan expires on September 12, 2025, or upon the earlier completion of all authorized transactions under such Rule 10b5-1 Plan.
+Added: the third quarter of 2024, none of our other directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement”
+Added: or “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408(a) of Registration S-K).
Articles of Incorporation of OptimizeRx Corporation (the “Company”) Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 (Registration No.
4 unchanged sentences
Incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
−Removed: Certification of Chief Executive Officer pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Chief Financial Officer pursuant to 18 U.S.C.
+Added: Certification of Chief
+Added: Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.
+Added: Certification of Chief
+Added: Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Chief
+Added: Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Inline XBRL Instance Document
−Removed: Inline XBRL Taxonomy Extension Schema Document
−Removed: Inline XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: Inline XBRL Taxonomy Extension Definition Linkbase Document
−Removed: Inline XBRL Taxonomy Extension Label Linkbase Document
−Removed: Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
−Removed: ** Provided herewith.
−Removed: Pursuant to the requirements of the Securities
−Removed: Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: OptimizeRx Corporation
−Removed: August 14, 2024
−Removed: /s/ William J.
+Added: Inline XBRL Taxonomy Extension Schema
+Added: Inline XBRL Taxonomy Extension Calculation
+Added: Linkbase Document
+Added: Inline XBRL Taxonomy Extension Definition
+Added: Linkbase Document
+Added: Inline XBRL Taxonomy Extension Label
+Added: Linkbase Document
+Added: Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Added: to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
+Added: the undersigned, thereunto duly authorized.
Chief Executive Officer
(principal executive officer)
−Removed: OptimizeRx Corporation
−Removed: August 14, 2024
−Removed: /s/ Edward Stelmakh
Edward Stelmakh
+Added: Edward Stelmakh
Chief Financial Officer and
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.